EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Clinicogenomic Characteristics and Treatment Outcomes of Patients With Advanced ALK -Rearranged Squamous and Adenosquamous Non–Small Cell Lung Cancers

Emily A Miao iD, Beow Yeap, Sameh Daher iD, Meghanne Lomibao iD, Fangdi Sun iD, Rachel Keogh iD, Jason Lambden, Amanda Reyes iD, Jennifer L Peterson, Joyce Liang, Audrey Liu, Andrew Do iD und 11 weitere

JCO Precision Oncology · 2026-03 · 10 (3)

DOI: 10.1200/po-25-01148 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JCO Precision Oncology, 2026-03. Verfasst von Emily A Miao und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Mass General Brigham Cancer Institute, Boston, MA. Hauptthemen laut MEDLINE: Anaplastic Lymphoma Kinase, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Adenosquamous. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Anaplastic lymphoma kinase (ALK) is an established therapeutic target in non–small cell lung cancer (NSCLC), predominantly identified in adenocarcinomas. However, ALK rearrangements also occur in de novo squamous and adenosquamous NSCLCs and their clinicogenomic features remain poorly defined. METHODS This multi-institutional retrospective analysis included patients with advanced ALK+ NSCLC. Patients with de novo ALK+ squamous and adenosquamous NSCLCs were identified and compared with an ALK+ adenocarcinoma cohort treated with first-line (1L) alectinib. Overall survival (OS), time to progression (TTP), and time to treatment discontinuation (TTD) were analyzed using the Kaplan-Meier methodology. RESULTS Among 177 patients, 29 had ALK+ squamous (n = 17) and adenosquamous (n = 12) NSCLCs and 148 had ALK+ adenocarcinoma treated with 1L alectinib. Among patients receiving 1L alectinib, OS was significantly shorter for patients with adenosquamous (median, 31.0 months [95% CI, 17.0 to not reached {NR}]) and squamous (27.0 months [95% CI, 5.0 to 35.0]) tumors compared with that for patients with adenocarcinoma (median NR; median follow-up 51.2 months; P < .001). TTP was shorter for squamous (median, 8.0 months [95% CI, 2.0 to 12.0]) versus adenocarcinoma (median, 19.0 months [95% CI, 12.6 to 25.0]) cohorts ( P < .001), although the adenosquamous cohort had comparable TTP (median, 20.0 months [95% CI, 9.4 to 30.6]) with the adenocarcinoma cohort ( P = .70). TTD was significantly shorter for squamous (median, 9.5 months [95% CI, 1.5 to 13.0]) and adenosquamous (median, 20.0 months [95% CI, 3.0 to 24.0]) versus adenocarcinoma cohorts (52.3 months [95% CI, 40.5 to 57.5]; P < .001). Genomic profiling revealed more frequent TP53 (53% v 25%; P = .026), PDGFRA (16% v 0%; P = .009), KIT (11% v 0%; P = .045), PIK3CA (11% v 0%; P = .045), and MYC (11% v 0%; P = .045) coalterations in the squamous/adenosquamous cohort. CONCLUSION ALK+ squamous and adenosquamous NSCLCs are rare, but biologically distinct, with inferior outcomes on 1L ALK TKI, highlighting the need for further research to develop effective treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anaplastic Lymphoma KinaseCarcinoma, Non-Small-Cell LungLung NeoplasmsCarcinoma, AdenosquamousCarcinoma, Squamous CellHumansFemaleMaleRetrospective StudiesMiddle AgedAgedTreatment OutcomePiperidinesGene RearrangementCarbazolesAdultProtein Kinase InhibitorsAged, 80 and over

Substanzen

Anaplastic Lymphoma KinaseALK protein, humanalectinibPiperidinesCarbazolesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Medicine, Mass General Brigham Cancer Institute, Boston, MA.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Division of Oncology, Department of Medicine, Stanford University, Stanford, CA.
  • Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.
  • Department of Medical Oncology, University of Colorado School of Medicine, Aurora, CO.
  • Department of Medicine, City of Hope Cancer Center, Duarte, CA.

ORCID-Profile: Emily A Miao, Sameh Daher, Meghanne Lomibao, Fangdi Sun, Rachel Keogh, Amanda Reyes, Andrew Do, Carrie Lee, Melinda Hsu, Joshua Reuss, Shirish M Gadgeel, Matthew Lee, Tejas Patil, Vincent Lam, Joel W Neal, Alexander Drilon, Jessica J Lin

Förderung

  • NCI NIH HHS

Zitieren

APA

Miao, E. A., Yeap, B., Daher, S., Lomibao, M., Sun, F., Keogh, R., Lambden, J., Reyes, A., Peterson, J. L., Liang, J., Liu, A., Do, A., Lee, C., Hsu, M., Evangelist, M., Reuss, J., Gadgeel, S. M., Lee, M., Patil, T., …, & Lin, J. J. (2026). Clinicogenomic Characteristics and Treatment Outcomes of Patients With Advanced ALK -Rearranged Squamous and Adenosquamous Non–Small Cell Lung Cancers. JCO Precision Oncology, 10(3). https://doi.org/10.1200/po-25-01148

Vancouver

Miao EA, Yeap B, Daher S, Lomibao M, Sun F, Keogh R, et al. Clinicogenomic Characteristics and Treatment Outcomes of Patients With Advanced ALK -Rearranged Squamous and Adenosquamous Non–Small Cell Lung Cancers. JCO Precision Oncology. 2026;10(3). doi:10.1200/po-25-01148

BibTeX
@article{Miao2026,
  author = {Miao, Emily A and Yeap, Beow and Daher, Sameh and Lomibao, Meghanne and Sun, Fangdi and Keogh, Rachel and Lambden, Jason and Reyes, Amanda and Peterson, Jennifer L and Liang, Joyce and Liu, Audrey and Do, Andrew and Lee, Carrie and Hsu, Melinda and Evangelist, Makenzi and Reuss, Joshua and Gadgeel, Shirish M and Lee, Matthew and Patil, Tejas and Lam, Vincent and Neal, Joel W and Drilon, Alexander and Lin, Jessica J},
  title = {Clinicogenomic Characteristics and Treatment Outcomes of Patients With Advanced ALK -Rearranged Squamous and Adenosquamous Non–Small Cell Lung Cancers},
  journal = {JCO Precision Oncology},
  year = {2026},
  volume = {10},
  number = {3},
  doi = {10.1200/po-25-01148}
}
Kostenlos starten →